Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Gilead Sciences (NASDAQ: GILD) has appointed Dietmar Berger, MD, PhD as its new Chief Medical Officer, effective January 2, 2025. Dr. Berger, who succeeds Merdad Parsey, MD, PhD, will oversee the company's global Development and Medical Affairs organizations, managing their virology, oncology, and inflammation portfolio.
Dr. Berger joins from Sanofi, where he served as Chief Medical Officer and Global Head of Development. With over 25 years of experience, he brings extensive expertise in developing innovative medicines across multiple therapeutic areas. His track record includes successful global filings for various cancer treatments and transformative products in immunology, hematology, and infectious diseases.
Gilead Sciences (NASDAQ: GILD) ha nominato Dietmar Berger, MD, PhD come nuovo Direttore Medico, con effetto dal 2 gennaio 2025. Il Dr. Berger, che succede a Merdad Parsey, MD, PhD, supervisionerà le organizzazioni globali di Sviluppo e Affari Medici dell'azienda, gestendo il portfolio relativo a virologia, oncologia e infiammazione.
Il Dr. Berger arriva da Sanofi, dove ha ricoperto il ruolo di Direttore Medico e Capo Globale dello Sviluppo. Con oltre 25 anni di esperienza, porta con sé una vasta esperienza nello sviluppo di farmaci innovativi in diversi ambiti terapeutici. La sua carriera include approvazioni globali di successo per vari trattamenti contro il cancro e prodotti trasformativi in immunologia, ematologia e malattie infettive.
Gilead Sciences (NASDAQ: GILD) ha nombrado a Dietmar Berger, MD, PhD como su nuevo Director Médico, con efecto a partir del 2 de enero de 2025. El Dr. Berger, quien sucede a Merdad Parsey, MD, PhD, supervisará las organizaciones globales de Desarrollo y Asuntos Médicos de la compañía, gestionando su cartera en virología, oncología e inflamación.
El Dr. Berger se une a Gilead desde Sanofi, donde se desempeñó como Director Médico y Jefe Global de Desarrollo. Con más de 25 años de experiencia, aporta una amplia experiencia en el desarrollo de medicamentos innovadores en múltiples áreas terapéuticas. Su trayectoria incluye presentaciones globales exitosas para diversos tratamientos contra el cáncer y productos transformadores en inmunología, hematología y enfermedades infecciosas.
길리어드 사이언스(Gilead Sciences) (NASDAQ: GILD)는 디트마르 베르거(Dietmar Berger), MD, PhD를 2025년 1월 2일자로 신임 최고 의학 책임자로 임명했습니다. 베르거 박사는 머르다드 파세이(Merdad Parsey), MD, PhD의 후임자로, 회사의 글로벌 개발 및 의학 업무 조직을 감독하며, 바이러스학, 종양학 및 염증 포트폴리오를 관리합니다.
베르거 박사는 글로벌 개발 책임자이자 최고 의학 책임자로 근무했던 사노피(Sanofi)에서 합류합니다. 25년 이상의 경험을 가진 그는 다양한 치료 분야에서 혁신적인 약물 개발에 대한 광범위한 전문성을 가지고 있습니다. 그의 경력에는 여러 암 치료법과 면역학, 혈액학 및 감염병에 대한 혁신적인 제품에 대한 성공적인 글로벌 승인 기록이 포함되어 있습니다.
Gilead Sciences (NASDAQ: GILD) vient de nommer Dietmar Berger, MD, PhD en qualité de nouveau Directeur Médical, à compter du 2 janvier 2025. Le Dr Berger, qui succède à Merdad Parsey, MD, PhD, supervisera les organisations mondiales de Développement et des Affaires Médicales de l'entreprise, gérant leur portefeuille en virologie, oncologie et inflammation.
Le Dr Berger rejoint Gilead en provenance de Sanofi, où il a occupé le poste de Directeur Médical et Responsable Mondial du Développement. Fort de plus de 25 ans d'expérience, il apporte une vaste expertise dans le développement de médicaments innovants dans plusieurs domaines thérapeutiques. Son parcours comprend des dépôts globaux réussis pour divers traitements contre le cancer et des produits transformateurs en immunologie, hématologie et maladies infectieuses.
Gilead Sciences (NASDAQ: GILD) hat Dietmar Berger, MD, PhD zu seinem neuen Chief Medical Officer ernannt, wirksam ab dem 2. Januar 2025. Dr. Berger tritt die Nachfolge von Merdad Parsey, MD, PhD, an und wird die globalen Entwicklungs- und medizinischen Angelegenheiten der Firma überwachen und dabei ihr Portfolio in den Bereichen Virologie, Onkologie und Entzündungen leiten.
Dr. Berger kommt von Sanofi, wo er als Chief Medical Officer und Global Head of Development tätig war. Mit über 25 Jahren Erfahrung bringt er umfassende Expertise in der Entwicklung innovativer Arzneimittel in mehreren therapeutischen Bereichen mit. Seine Erfolgsbilanz umfasst erfolgreiche globale Zulassungen für verschiedene Krebsbehandlungen und transformative Produkte in der Immunologie, Hämatologie und Infektionskrankheiten.
- Appointment of experienced executive with 25+ years in drug development
- Strong track record in successful global drug filings across multiple therapeutic areas
- Expertise aligns with Gilead's core focus areas (virology, oncology, inflammation)
- 12-month gap until new CMO takes position (January 2025)
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company’s leading virology, oncology and inflammation portfolio and will oversee the company’s global Development and Medical Affairs organizations.
“Dietmar’s exceptional leadership in global drug development, his track record in delivering transformational therapies, and the breadth and depth of his experience make him an ideal choice as Gilead’s Chief Medical Officer,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “We are delighted to welcome Dietmar to Gilead at a time when we are poised to extend our leadership in virology and deliver on our significant potential in oncology and inflammation. We look forward to having Dietmar take up his role at the beginning of 2025 as we work to strengthen our impact for patients and communities worldwide.”
“I’m honored to join Gilead, an organization I have long admired as an industry leader and one of the world’s most innovative companies, whose transformative therapies have revolutionized the treatment, prevention and cure for some of healthcare’s greatest challenges,” said Dr. Berger. “I am looking forward to working with the talented team at Gilead to continue to advance its promising pipeline and improve health outcomes for communities around the world.”
Most recently, Dr. Berger was the Chief Medical Officer and Global Head of Development at Sanofi, where he led development science, strategy and operations across the company’s therapeutic areas of focus. Prior to Sanofi, Dr. Berger served in senior development roles at Atara, Genentech, Bayer and Amgen.
Across a distinguished career in drug development, Dr. Berger has delivered an impressive track record of successful global filings, including multiple cancer treatments, as well as transformative products in other disease areas including immunology, hematology, oncology, and infectious diseases.
Dr. Berger completed his medical training in Freiburg (
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead may not complete the leadership transition within currently anticipated timelines or at all; challenges that Gilead may encounter in implementing the leadership transition; the ability of Gilead to realize the full potential of its pipeline; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212608966/en/
Ashleigh Koss, Media
public_affairs@gilead.com
Jacquie Ross, Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
When will Dietmar Berger start as Gilead's (GILD) new Chief Medical Officer?
What are Dr. Berger's main responsibilities at GILD?
What was Dr. Berger's previous position before joining GILD?
Who is Dr. Berger replacing as Chief Medical Officer at GILD?
What is Dr. Berger's background and experience?
